ABT stock forecast, quote, news & analysis

Key Takeaways

• ABT stock declined approximately -14% over the past 30 days, driven primarily by a post-earnings sell-off following Q1 results and lowered full-year profit guidance due to the Exact Sciences acquisition.
• Over the past quarter, the stock fell around -20%, reflecting broader pressures from weaker nutrition and diagnostics segments amid a challenging respiratory season.
• The $21 billion Exact Sciences deal, completed in late March, added strategic oncology exposure but introduced $0.20 EPS dilution, weighing on near-term sentiment.
• Despite beats on Q1 earnings and revenue, shares dropped sharply on margin concerns and integration costs.
• Analyst price target cuts post-earnings contributed to downward momentum in the healthcare sector.

Abbott Laboratories (ABT) Company Overview and Market Position

Abbott Laboratories (ABT) is a global healthcare company that develops, manufactures, and markets a diverse portfolio of medical products, including diagnostics, nutritional supplements, medical devices, and established pharmaceuticals. Its core business spans four segments: diagnostics (testing and monitoring), nutrition (pediatric and adult products like Similac), medical devices (such as FreeStyle Libre continuous glucose monitors and cardiovascular stents), and established pharmaceuticals.

Abbott holds a strong competitive position in high-growth areas like diabetes care and structural heart devices, with significant international exposure (about 60% of sales). Its diversified model provides resilience, but recent stock price movement reflects vulnerabilities in nutrition recovery and diagnostics tied to seasonal demand, exacerbated by acquisition-related costs.

Abbott Laboratories (ABT) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, ABT stock has declined by approximately -14%, trading in a volatile, trend-driven downtrend from around $102 in early April to a recent close near $87.50. The sharpest drop occurred post-Q1 earnings on April 16, with shares falling over 5% in a single session amid heavy volume.

For the past quarter, the stock is down about -20%, from roughly $109 in early February. The movement has been range-bound early on but accelerated into a steady decline in March and April, influenced by market trends in healthcare and company-specific catalysts. Volatility spiked around earnings and acquisition news, with the 52-week low recently tested.

What Drove ABT Stock Price in the Last 30 Days

The primary catalyst for ABT's 30-day decline was the Q1 2026 earnings release on April 16, where adjusted EPS of $1.15 beat estimates slightly ($1.14 expected), and revenue hit $11.16 billion, topping $11.03 billion forecasts. However, a weaker-than-expected flu season hurt diagnostics, and ongoing nutrition segment challenges persisted.

Most critically, Abbott trimmed its full-year adjusted EPS guidance to a midpoint of $5.48 (from prior $5.55-$5.80), factoring in $0.20 dilution from the March 23 Exact Sciences acquisition (valued at $21 billion equity, $23 billion enterprise). Shares plunged 4.7%-5% immediately after, as investors focused on short-term margin pressures over long-term oncology growth.

Analyst reactions amplified the move, with firms like Piper Sandler, Oppenheimer, and RBC Capital cutting price targets (e.g., Piper from $135 to $115). Sector sentiment in healthcare, amid broader market rotation, added downward pressure. Positive notes like FDA clearance for Ultreon 3.0 AI imaging software on April 28 provided minor support but failed to reverse the trend.

What Drove ABT Stock Performance Over the Last Quarter

The quarter's -20% drop built on Q4 2025 revenue miss ($11.46 billion vs. $11.8 billion expected), signaling nutrition weakness and diagnostics normalization post-COVID. Early quarter trading was range-bound around $110, but March's Exact Sciences close (March 23) introduced dilution concerns ahead of Q1 results.

Macro factors like moderating demand in respiratory testing and inflation in healthcare costs compounded segment issues. Institutional selling followed, with the stock breaking key supports. Competitive dynamics in medical devices remained solid (e.g., FreeStyle Libre growth), but cumulative EPS guidance cuts and healthcare sector underperformance (vs. S&P 500) dominated, leading to sustained price erosion.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from hundreds available, which analyze and trade thousands of tickers across various markets. These curated bots highlight those with the strongest recent performance, relevance to current market trends, and diversity in strategies—such as trend-following, mean reversion, or momentum-based approaches—across short-term, medium-term, and long-term timeframes. Key metrics like win rate, profit factor, and Sharpe ratio help users gauge effectiveness. Whether seeking high-frequency scalpers or swing traders, this section offers transparent insights into live bot activity. Explore Trending AI Robots to discover tools that could enhance your stock analysis and trading decisions.

ABT Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor Q2 earnings for updates on Exact Sciences integration, nutrition recovery, and diagnostics rebound. Upcoming FDA developments, including potential expansions for Ultreon 3.0 or FreeStyle Libre, could signal device momentum.

Industry trends like AI in diagnostics and oncology screening growth remain key, alongside macro factors such as interest rates impacting M&A and healthcare spending. Strategic moves in biosimilars and partnerships (e.g., Epic integration) warrant attention. Risks include prolonged nutrition headwinds, regulatory hurdles, or sector rotation; catalysts may emerge from synergy realizations or beat guidance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.